Last reviewed · How we verify
AK112, Gemcitabine, Cisplatin
AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, while gemcitabine and cisplatin are chemotherapy agents that damage tumor DNA.
AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, while gemcitabine and cisplatin are chemotherapy agents that damage tumor DNA. Used for Biliary tract cancer (phase 3), Non-small cell lung cancer (investigational).
At a glance
| Generic name | AK112, Gemcitabine, Cisplatin |
|---|---|
| Sponsor | Akeso |
| Drug class | Bispecific antibody (PD-1/LAG-3 inhibitor) combined with chemotherapy |
| Target | PD-1 and LAG-3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AK112 blocks two immune checkpoints (PD-1 and LAG-3) to reinvigorate exhausted T cells, while gemcitabine (a nucleoside analog) and cisplatin (a platinum agent) induce DNA damage and apoptosis in cancer cells. This combination approach aims to synergize checkpoint inhibition with direct cytotoxic chemotherapy for enhanced anti-tumor efficacy.
Approved indications
- Biliary tract cancer (phase 3)
- Non-small cell lung cancer (investigational)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Immune-related adverse events (irAEs)
Key clinical trials
- A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors (PHASE1, PHASE2)
- AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer (PHASE3)
- Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK112, Gemcitabine, Cisplatin CI brief — competitive landscape report
- AK112, Gemcitabine, Cisplatin updates RSS · CI watch RSS
- Akeso portfolio CI